CUAMC
AVIR icon

China Universal Asset Management Company’s Atea Pharmaceuticals AVIR Stock Holding History

China Universal Asset Management Company’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.6K Buy
13,864
+1,133
+9% +$5.2K 0.01% 431
2025
Q4 		$45.5K Sell
12,731
-1,179
-8% -$3.75K ﹤0.01% 460
2025
Q3 		$40.3K Sell
13,910
-3,278
-19% -$11.2K ﹤0.01% 443
2025
Q2 		$61.9K Buy
17,188
+246
+1% +$734 0.01% 406
2025
Q1 		$50.7K Sell
16,942
-967
-5% -$3.02K ﹤0.01% 420
2024
Q4 		$60K Buy
17,909
+1,672
+10% +$5.56K 0.01% 440
2024
Q3 		$54.4K Buy
16,237
+6,343
+64% +$23K 0.01% 382
2024
Q2 		$32.7K Sell
9,894
-6,285
-39% -$23.4K ﹤0.01% 378
2024
Q1 		$65.4K Buy
16,179
+6,526
+68% +$25.5K 0.01% 398
2023
Q4 		$29.4K Buy
9,653
+7,514
+351% +$22.8K 0.01% 402
2023
Q3 		$6.42K Buy
2,139
+1,046
+96% +$3.56K ﹤0.01% 374
2023
Q2 		$4.09K Sell
1,093
-36
-3% -$135 ﹤0.01% 386
2023
Q1 		$3.78K Buy
1,129
+283
+33% +$1.15K ﹤0.01% 393
2022
Q4 		$4.07K Buy
846
+66
+8% +$334 ﹤0.01% 318
2022
Q3 		$4K Buy
+780
New +$5.97K ﹤0.01% 289

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

China Universal Asset Management Company's AVIR Position: Q1 2026 in Review

China Universal Asset Management Company increased its Atea Pharmaceuticals (AVIR) stake by 8.9% in Q1 2026, buying an estimated $5.2K and bringing the position to 13,864 shares worth $74.6K. The position accounts for 0.01% of the portfolio, ranked #431.

China Universal Asset Management Company first reported a position in AVIR in Q3 2022 and has held it in 15 quarters since. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • China Universal Asset Management Company held 13,864 shares of Atea Pharmaceuticals worth $74.6K as of Q1 2026.
  • China Universal Asset Management Company bought 1,133 Atea Pharmaceuticals shares in Q1 2026, an estimated $5.2K.
  • Atea Pharmaceuticals made up 0.01% of China Universal Asset Management Company's portfolio in Q1 2026, its #431 holding.
  • China Universal Asset Management Company first reported a position in Atea Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on China Universal Asset Management Company's 13F filing for Q1 2026, filed 28 Apr 2026.